Theravance Biopharma (TBPH) Cash & Equivalents Growth (3y) (2017 - 2026)
Powered by 
Analysis
Theravance Biopharma (TBPH) Cash & Equivalents Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -23.18% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 14.34% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 37.45% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -27.97% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.85% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | 27.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.67% |
| Mar 31, 2026 | 15.36% |
| Dec 31, 2025 | -17.44% |
| Sep 30, 2025 | -25.26% |
| Jun 30, 2025 | 47.82% |
| Mar 31, 2025 | 5.44% |
| Dec 31, 2024 | -25.10% |
| Sep 30, 2024 | -42.26% |
| Jun 30, 2024 | -39.08% |
| Mar 31, 2024 | -22.13% |
| Dec 31, 2023 | -21.41% |
| Sep 30, 2023 | -8.40% |
| Jun 30, 2023 | 0.27% |
| Mar 31, 2023 | -17.38% |
| Dec 31, 2022 | 72.53% |
| Sep 30, 2022 | 59.88% |
| Jun 30, 2022 | -21.19% |
| Mar 31, 2022 | -24.95% |
| Dec 31, 2021 | -38.03% |
| Sep 30, 2021 | 6.26% |